Bristol's Opdivo proves effective against second type of lung cancer

April 17 (Reuters) - A large study of Bristol-Myers Squibb Co's Opdivo treatment has been halted after proving the drug is effective against a common form of lung cancer, the company said, positioning the medicine for far wider use than its already approved lung cancer and melanoma indications.